Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,290 papers from all fields of science
Search
Sign In
Create Free Account
Discontinuation (procedure)
Known as:
discontinuation
, discontinuations
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
Anne F. Luetkemeyer
,
Cheryl Mcdonald
,
M. Ramgopal
,
S. Noviello
,
R. Bhore
,
Peter Ackerman
Clinical Infectious Diseases
2016
Corpus ID: 21865339
In human immunodeficiency virus (HIV)-hepatitis C virus-coinfected patients, 12 weeks' daclatasvir + sofosbuvir once-daily…
Expand
Highly Cited
2008
Highly Cited
2008
Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine Clinical Use
M. Michel
,
U. Wetterauer
,
Monika Vogel
,
J. Rosette
Drug Safety
2008
Corpus ID: 36426721
AbstractBackground: Muscarinic receptor antagonists are the standard of care for patients with overactive bladder (OAB). However…
Expand
Highly Cited
2007
Highly Cited
2007
Peginterferon α‐2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients
M. Kuboki
,
S. Iino
,
+5 authors
T. Sakai
Journal of Gastroenterology and Hepatology
2007
Corpus ID: 11810421
Background: The efficacy and safety of peginterferon alpha‐2a (40 KD) (peg‐IFNα‐2a) plus ribavirin has not been reported for…
Expand
Highly Cited
2007
Highly Cited
2007
Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137
S. Ramanathan
,
G. Shen
,
A. Cheng
,
B. Kearney
Journal of Acquired Immune Deficiency Syndromes
2007
Corpus ID: 31756102
Objectives:To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil…
Expand
Highly Cited
2006
Highly Cited
2006
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
D. Cohn
,
S. Valmadre
,
K. Resnick
,
L. Eaton
,
L. Copeland
,
J. Fowler
Gynecologic Oncology
2006
Corpus ID: 39133131
Highly Cited
2004
Highly Cited
2004
Zonisamide treatment for symptomatic infantile spasms
T. Lotze
,
A. Wilfong
Neurology
2004
Corpus ID: 8642571
The authors evaluated zonisamide for symptomatic infantile spasms in 23 patients. Spasm cessation, EEG evolution, and…
Expand
Highly Cited
2003
Highly Cited
2003
Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain.
A. Gammaitoni
,
B. Galer
,
P. Lacouture
,
J. Domingos
,
T. Schlagheck
Pain medicine (Malden, Mass.)
2003
Corpus ID: 40269623
OBJECTIVE To evaluate the analgesic effectiveness/safety of the new oxycodone 7.5- and 10-mg/acetaminophen 325-mg (Percocet…
Expand
Highly Cited
1997
Highly Cited
1997
Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
Patrizio Lorenzi
,
S. Yerly
,
+6 authors
B. Hirschel
AIDS (London)
1997
Corpus ID: 25832647
Objective:To assess the safety, efficacy and plasma drug levels of the combination of ritonavir plus saquinavir for the treatment…
Expand
Highly Cited
1994
Highly Cited
1994
Is Baseline Agitation a Relative Contraindication for a Selective Serotonin Reuptake Inhibitor: A Comparative Trial of Fluoxetine Versus Imipramine
G. Tollefson
,
J. Greist
,
+4 authors
Kenneth Koback
Journal of Clinical Psychopharmacology
1994
Corpus ID: 27645527
A common presentation for major depression includes psychomotor agitation. However, this subtype has been the infrequent subject…
Expand
Highly Cited
1984
Highly Cited
1984
The relation of P3b to prior events and future behavior
R. Munson
,
D. Ruchkin
,
W. Ritter
,
S. Sutton
,
N. Squires
Biological Psychology
1984
Corpus ID: 7959871
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE